Form 8-K ARRAY BIOPHARMA INC For: Feb 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Array BioPharma (ARRY) PT Raised to $20 at Leerink Partners
February 7, 2018 7:40 AM ESTLeerink Partners raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $19.00) while maintaining a Outperform rating.
... MoreArray BioPharma (ARRY) PT Raised to $23 at Stifel
February 7, 2018 6:27 AM ESTStifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "The disclosure of median OS data from the P3 COLUMBUS trial (encorafenib/binimetinib vs. vemurafenib in BRAF-mutant melanoma) provides further confirmation of the pharmacological... More
